- Home
- TOP vs KYNB Comparison
TOP vs KYNB Comparison
Compare TOP & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | KYNB |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 31.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TOP | KYNB |
|---|---|---|
| Price | $0.90 | $7.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.3K | ★ 31.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $6.67 |
| 52 Week High | $3.33 | $9.58 |
Technical Indicators
Market Signals| Indicator | TOP | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 25.48 | 49.46 |
| Support Level | N/A | $7.37 |
| Resistance Level | $1.13 | $7.65 |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 0.07 | 73.47 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.